Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients
Clinical Transplantation · 2023
DOI: 10.1111/ctr.15041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2023. Verfasst von Maura L Kreiser und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, U…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Neutropenia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) is a common infection in abdominal transplant recipients (ATR). Prevention of CMV in the highest risk population (CMV IgG donor+/recipient‐) is critical as CMV is associated with negative outcomes. Guideline recommended prophylactic valganciclovir dosing is 900 mg daily for 6 months in this population. However, reduced dosing strategies are utilized in practice.
Methods
This single center, retrospective study in adult ATR compared full valganciclovir prophylactic dosing (900 mg daily for 6 months) to reduced dosing (900 mg daily for 3 months, then 450 mg daily for 3 months). The primary endpoint was incidence of CMV infection with viral load >1000 IU/mL. Secondary endpoints included incidence of CMV infection with viral load 200–1000 IU/mL, neutropenia, and leukopenia.
Results
Incidence of CMV infection with viral load >1000 IU/mL (29% vs. 27%, p = 1) or CMV infection with viral load 200‐1000 IU/mL (6% vs. 12%, p = .421) did not differ significantly between 68 ATR in reduced and full dosing groups, as well as incidence of leukopenia (94% vs. 97%, p = 1) and neutropenia (77% vs. 70%, p = .586).
Conclusions
There was no difference in the incidence of CMV infection, neutropenia, or leukopenia of the two dosing regimens, although time to CMV diagnosis was different.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.
ORCID-Profile: Maura L Kreiser, Kristen R Szempruch
Zitieren
APA
Kreiser, M. L., Dupuis, R., Szempruch, K. R., & Chargualaf, L. M. (2023). Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15041
Vancouver
Kreiser ML, Dupuis R, Szempruch KR, Chargualaf LM. Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients. Clinical Transplantation. 2023. doi:10.1111/ctr.15041
BibTeX
@article{Kreiser2023,
author = {Kreiser, Maura L and Dupuis, Robert and Szempruch, Kristen R and Chargualaf, Laura M},
title = {Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.15041}
}
EUVIMED